Krebs Biochemicals & Industries Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 129.77 million compared to INR 90.91 million a year ago. Revenue was INR 130.07 million compared to INR 91.14 million a year ago. Net loss was INR 49.77 million compared to INR 55.54 million a year ago. Basic loss per share from continuing operations was INR 2.31 compared to INR 2.58 a year ago. Diluted loss per share from continuing operations was INR 2.31 compared to INR 2.58 a year ago.
For the nine months, sales was INR 384.49 million compared to INR 406.74 million a year ago. Revenue was INR 386.9 million compared to INR 411.01 million a year ago. Net loss was INR 138.82 million compared to INR 177.52 million a year ago. Basic loss per share from continuing operations was INR 6.44 compared to INR 8.23 a year ago. Diluted loss per share from continuing operations was INR 6.44 compared to INR 8.23 a year ago.